Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.

PURPOSE To review the frequency and location of malignancies detected after prophylactic salpingo-oophorectomy in women with BRCA mutations. METHODS Medical records and pathology findings were reviewed from BRCA-positive women undergoing prophylactic surgery for ovarian cancer risk reduction who underwent complete examination of the adnexa. Patients undergoing this procedure between January 1999 and January 2007 were identified. RESULTS From January 1999 to January 2007, 122 BRCA-positive patients underwent prophylactic surgery in the Division of Gynecologic Oncology at Brigham and Women's Hospital. The median age was 46.5 years (range, 33 to 76 years). Seven (5.7%) were found to have an early malignancy in the upper genital tract and all patients were age > or = 44 years at diagnosis. Of seven consecutive cancers culled between January 1999 and January 2007, all (100%) originated in the fimbrial or ampullary region of the tube; six had an early (intraepithelial) component. Two were associated with surface implants on the ovary and two required repeated sectioning to detect microscopic carcinomas in the fimbria. CONCLUSION The distal fallopian tube seems to be the dominant site of origin for early malignancies detected in approximately 6% of women undergoing ovarian cancer risk-reduction surgery. The greatest proportion of serous cancer risk in BRCA mutation-positive women should be assigned to the fimbria rather than the ovary, and future clinical and research protocols should employ thorough examination of the fimbria, including multiple sections from each tissue block, to maximize detection of early malignancies in this population.

[1]  Rochelle L. Garcia,et al.  Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations. , 2004, The American journal of surgical pathology.

[2]  Christopher P Crum,et al.  The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome , 2006, The American journal of surgical pathology.

[3]  M. Beattie,et al.  Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Colgan Challenges in the Early Diagnosis and Staging of Fallopian-Tube Carcinomas Associated with BRCA Mutations , 2003, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[5]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[6]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[7]  R. Berkowitz,et al.  Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship , 2007, The American journal of surgical pathology.

[8]  H. Mefford,et al.  BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. , 1997, American journal of human genetics.

[9]  M. Muto,et al.  Advances in the Recognition of Tubal Intraepithelial Carcinoma: Applications to Cancer Screening and the Pathogenesis of Ovarian Cancer , 2006, Advances in anatomic pathology.

[10]  J. Niloff,et al.  Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. Colgan,et al.  Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. , 2006, Gynecologic oncology.

[12]  B. Rosen,et al.  Occult Carcinoma in Prophylactic Oophorectomy Specimens: Prevalence and Association With BRCA Germline Mutation Status , 2001, The American journal of surgical pathology.

[13]  J. Garber,et al.  A candidate precursor to serous carcinoma that originates in the distal fallopian tube , 2007 .

[14]  B. Karlan,et al.  BRCA-Mutation–Associated Fallopian Tube Carcinoma: A Distinct Clinical Phenotype? , 2005, Obstetrics and gynecology.

[15]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[16]  Rochelle L. Garcia,et al.  Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. , 2001, Gynecologic oncology.

[17]  P. V. van Diest,et al.  Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. , 2000, Gynecologic oncology.

[18]  A. McEwen,et al.  Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy. , 2004, Gynecologic oncology.

[19]  Rochelle L. Garcia,et al.  Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. , 2006, American journal of obstetrics and gynecology.

[20]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[21]  Rochelle L. Garcia,et al.  Pathologic findings in prophylactic oophorectomy specimens in high-risk women. , 2002, Gynecologic oncology.

[22]  G. Wiesner,et al.  Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. , 2000, Gynecologic oncology.

[23]  T. Rebbeck,et al.  Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Olufunmilayo I. Olopade,et al.  Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation , 2006 .

[25]  R. Knapp,et al.  Unifocal origin of advanced human epithelial ovarian cancers. , 1992, Cancer research.

[26]  S. Cannistra Cancer of the ovary. , 1993, The New England journal of medicine.

[27]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[28]  M. King,et al.  Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.